Ascendis Pharma A/S (ASND) Earnings History
Profitable14 years of earnings data (2012–2025) · Positive TTM net income
Loading earnings history...
Ascendis Pharma A/S (ASND) Earnings Overview
As of June 28, 2026, Ascendis Pharma A/S (ASND) reported trailing twelve-month net income of $507M, reflecting +44.6% year-over-year growth. The company earned $7.85 per diluted share over the past four quarters, with a net profit margin of -31.7%.
Looking at the long-term picture, ASND's historical earnings data spans multiple years. The company achieved its highest annual net income of $4M in fiscal 2013.
Ascendis Pharma A/S maintains positive profitability with a gross margin of 85.1%, operating margin of -18.9%, and net margin of -31.7%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including IONS (-$327M net income, -40.4% margin), INCY ($1.43B net income, 25.0% margin), ALKS ($153M net income, 16.4% margin), ASND has outperformed on profitability metrics. Compare ASND vs IONS →
ASND Earnings vs Peers
Earnings metrics vs comparable public companies
ASND Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$219M | +42.1% | -$131M | $-3.62 | -31.7% | -18.9% |
| 2024 | -$378M | +21.5% | -$279M | $-6.53 | -104.0% | -76.7% |
| 2023 | -$481M | +17.4% | -$456M | $-8.55 | -180.5% | -170.8% |
| 2022 | -$583M | -52.0% | -$562M | $-10.40 | -1139.6% | -1097.9% |
| 2021 | -$384M | +8.4% | -$452M | $-7.00 | -4931.6% | -5808.6% |
| 2020 | -$419M | -92.2% | -$331M | $-8.28 | -6025.5% | -4755.1% |
| 2019 | -$218M | -67.6% | -$227M | $-4.69 | -1630.0% | -1695.1% |
| 2018 | -$130M | -5.0% | -$155M | $-3.17 | -1229.5% | -1462.6% |
| 2017 | -$124M | -80.9% | -$112M | $-3.68 | -8097.8% | -7290.3% |
| 2016 | -$69M | -108.1% | -$73M | $-2.58 | -1487.3% | -1583.2% |
| 2015 | -$33M | -240.9% | -$42M | $-1.39 | -405.5% | -515.2% |
| 2014 | -$10M | -336.8% | -$12M | $-0.57 | -69.1% | -85.7% |
| 2013 | $4M | +226.3% | $5M | $0.38 | 20.0% | 25.9% |
| 2012 | $1M | - | $2M | $0.12 | 8.0% | 9.7% |
Download Data
Export ASND earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ASND — Frequently Asked Questions
Quick answers to the most common questions about buying ASND stock.
What is ASND earnings per share (EPS)?
ASND trailing twelve-month (TTM) diluted EPS is $7.85, reflecting +44.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.
What is Ascendis Pharma A/S's net income?
Ascendis Pharma A/S (ASND) trailing twelve-month net income is $507M as of 2025. Earnings grew +44.6% year-over-year.
Is ASND profitable?
Yes, ASND is profitable with a TTM net income of $507M and a net profit margin of -31.7%.
What is ASND's earnings growth rate?
ASND compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.
What are ASND's profit margins?
Ascendis Pharma A/S net profit margin is -31.7%, operating margin is -18.9%, and gross margin is +85.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is ASND growing earnings?
Yes, ASND earnings are accelerating — EPS growth of +44.6% exceeds the 5-year CAGR of N/A. TTM net income reached $507M. Earnings momentum is strengthening.
What was ASND's best earnings year?
Ascendis Pharma A/S's highest annual net income on record is $4M, achieved in fiscal year 2013. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.
What were ASND's earnings last quarter?
ASND's most recent reported quarter was Q1 2026. Net income was $640M with diluted EPS of $9.91. For a full breakdown of all quarters, see the quarterly earnings table on this page.